It is worth noting that paradoxically, PGC-1α against various treatments may have different effects that not only by fewer levels of expression tumor-suppressive and inhibition of angiogenesis effects but also by greater rates of expression led to antioxidant defense effects which depending on the circumstances both are useful in BC and CVD patients. The gene discussed is PPARGC1A; the disease is neoplasm.